Personalized biomarkers to monitor disease progression in advanced non-small cell lung cancer patients treated with icotinib

SONG Gaoguang; LIU Yujie; WANG Yanying; REN Guanjun; GUO Shuai; REN Junling; ZHANG Li; LI Zhili

Chinese︱Feedback︱Save this page

• Elaborating Academic Views 　　　　 • Exchanging Innovative Ideas
• Protecting Intellectual Properties 　　• Fast Sharing Science Papers

Sponsored by the Center for Science and Technology Development of the Ministry of Education
Supervised by Ministry of Education of the People's Republic of China

Home > Papers

Personalized biomarkers to monitor disease progression in advanced non-small cell lung cancer patients treated with icotinib

SONG Gaoguang 1,LIU Yujie 1,WANG Yanying 1,REN Guanjun 2,GUO Shuai 1,REN Junling 1,ZHANG Li 2,LI Zhili 1 * #

1.Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, 100005

2.Department of Respiration, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, 100730

*Correspondence author

#Submitted by

Subject:

Funding: Research Fund for the Doctoral Program of Higher Education （No.No. 20121106110023) to Z. Li）

Opened online:16 May 2016

Accepted by: none

Citation: SONG Gaoguang,LIU Yujie,WANG Yanying.Personalized biomarkers to monitor disease progression in advanced non-small cell lung cancer patients treated with icotinib[OL]. [16 May 2016] http://en.paper.edu.cn/en_releasepaper/content/4688117

Disease-specific humoral immune response-related protein complexes in blood are associated with disease progression. 31 patients with stage IIIB and IV non-small cell lung cancer (NSCLC) were administered with oral dose of icotinib hydrochloride (150 mg bid or 125 mg tid) for a 28-continuous-day cycle until diseases progressed or unacceptable toxicity occurred. The levels of immunoinflammation-related protein complexes (IIRPCs) in a series of plasma samples from 31 NSCLC patients treated with icotinib hydrochloride were determined by an optimized native-PAGE gel. Our results indicate that the time length of humoral immune and inflammation response (TLHIIR) was closely associated with disease progression, and the median TLHIIR was 22.0 weeks, 95% confidence interval (CI): 16.2 to 33.0 weeks, with a lead time of median 11 weeks related to clinical imaging evidence confirmed by computed tomography or magnetic resonance imaging (the median of progression-free survival, 34.0 weeks, 95% CI: 27.9 to 49.0 weeks). Our findings suggest the existence of a complex relationship between humoral immune response, acquired resistance, and disease progression. Personalized IIRPCs could be an excellent indicator to monitor the disease progression.

Keywords:Immunoinflammation-related protein complexes; non-small cell lung cancer; time length of humoral immune and inflammatory response; time length of disease progression; progression-free survival

For this paper

● PDF (0B)
● Revision 0 　　
● Print this paper
● Recommend this paper to a friend
● Add to my favorite list

Saved Papers

Please enter a name for this paper to be shown in your personalized Saved Papers list

Tags

Add yours

Related Papers

Statistics

PDF Downloaded	24
Bookmarked	0
Recommend	0
Comments	Array

Submit your papers

Alert Name:
Alerting to:
Authentication email will be sent to your email address in 24 hours
Frequency:
Email Message Format:	Plain text Graphical(HTML)

Complete the form below and we will recommend the selected titles to your friends on your behalf. * Indicates a required field.
Your name*:
Your email address*:
Recipient's name*:
Recipient's email address*:
(multiple recipient's names and email addresses should be separated with semicolons)
Your comments:	I thought you would find the page(s) useful.

Your name:
Your email address:
Recipient's name:
Recipient's email address:
(multiple recipient's names and email addresses should be separated with semicolons)
Your comments:	I thought you would find this page useful.

Disclaimer: This message was sent to your friend using the "Send it to a friend" facility on the Sciencepaper Online’ WWW site, http://www.paper.edu.cn/en. The Sciencepaper Online is not responsible for the content of this email, and anything said in this email does not necessarily reflect the Sciencepaper Online's views.

	Check out RSS, or use RSS reader to subscribe this item

Saved Papers